The PRECEDE Consortium, through its unique new model of cooperation from leading pancreatic centers around the world, is designed to transform our ability to detect pancreatic cancer early and markedly change survival for this deadly disease.
-Dr. Diane Simeone, NYU
By joining patients from across the globe, you can help forever change the course of pancreatic cancer.
-Dr. Aaron Grossberg, OHSU
Your participation in PRECEDE is important. We have so much to learn how to prevent and detect this deadly disease.
-Dr. Steven Gallinger, UHN
The Pancreatic Cancer Early Detection (PRECEDE) Consortium is an international, multi-institutional collaborative group of experts to increase survival for pancreatic cancer patients by improving early detection, screening, risk modeling and prevention for those with a heritable risk for pancreatic cancer, through a novel model of collaboration and data sharing. PRECEDE’s mission is to transform the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 10% to 50% within the next 10 years.
With over 30 leading academic medical centers across the globe, PRECEDE has assembled the largest high-risk patient cohort, with longitudinal clinical data and biospecimen acquisition and tracking.
Pancreatic cancer is one of the world’s deadliest cancers, with a 5-year survival rate of just 10%. In the United States it’s the 3rd most deadly cancer, and about 70% of patients die within 1 year of diagnosis. Globally, pancreatic cancer is the 7th leading cause of death. Both the incidence and mortality of pancreatic cancer are still increasing, while deaths from other cancers are declining. Pancreatic cancer is projected to become the 2nd leading cause of cancer-related deaths in the U.S. by 2030.
Why is pancreatic cancer so difficult to detect and treat? Of the many factors, here are a few:
• There is no simple screening test or other early detection tool for the disease, and its earliest symptoms are non-specific.
• By the time disease-specific symptoms warrant a visit to a doctor, the cancer often has already spread to other organs and, by then, is inoperable.
• Early detection and prevention would dramatically change the trajectory of pancreatic cancer, saving tens of thousands of lives each year.
PRECEDE's mission is to increase the pancreatic cancer 5-year survivial rate from 10% to 50% in the next 10 years!
The PRECEDE Consortium is an observational longitudinal prospective cohort study, with serial biosample collection (every 6-12 months) and acquisition of standardized clinical and imaging data in defined high-risk groups.
Through this effort, it will bring together clinicians, basic researchers, patients, biopharmaceutical and technology companies to accelerate new approaches to early detection and prevention of pancreatic cancer. The PRECEDE Consortium will be an innovation hub, disseminating new protocols and discoveries. We will apply a technology-rich, data-driven, integrated model of basic, translational, and clinical research to early detection and prevention. Specific goals of the consortium are:
• To maximize identification of high risk individuals and to advance early detection research and clinical care
• To develop and validate an early detection blood or other test for pancreatic cancer
• To understand pancreatic cancer risk, including discovering pancreatic cancer susceptibility genes
• To formulate and execute a strategic plan for pancreatic cancer prevention